CYHS2200504国 2023S01864 | 托拉塞米片 | | --- | | Torasemide Tablets | | 托拉塞米 | | 片剂 药品注册(境内生产) | | 10mg 化学药品4类 | | YBH17822023 24个月 | | 每盒10片（10片/板，1板/盒），每盒20片（10 片/板，2板/盒），每30片（10片/板，3板/ 处方药 | | 盒），每盒60片（10片/板，6板/盒）。 | | 根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注 册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、标签及生产 | | 工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求方可生产销 | | 售。 | | 南京海辰药业股份有限公司 | | 南京经济技术开发区恒发路1号 | | 南京海辰药业股份有限公司 | | 南京经济技术开发区恒发路1号 | | 国药准字H20234532 2028年11月20日 | | 生产工艺信息表,质量标准,说明书,标签 | | 南京海辰药业股份有限公司 | | 江苏省药品监督管理局,江苏省食品药品监督检验研究院,中国食品药 ...

Financial Performance - The company's operating revenue for Q3 2023 was CNY 116,400,513.71, representing a 4.27% increase year-over-year[5]. - Net profit attributable to shareholders for Q3 2023 was CNY 2,947,505.95, an increase of 24.84% compared to the same period last year[5]. - The company's basic earnings per share for Q3 2023 was CNY 0.0246, up 24.87% from the same period last year[5]. - Net profit for the period increased to CNY 22,422,432.46, up 13.4% from CNY 19,757,915.43 in the same period last year[18]. - Earnings per share (EPS) rose to CNY 0.1869, compared to CNY 0.1674 in the previous period, marking an increase of 10.5%[19]. Cash Flow - The net cash flow from operating activities reached CNY 19,474,793.85, a significant increase of 136.33% year-over-year[9]. - The net cash flow from operating activities was ¥19,474,793.85, a decrease of ¥53,606,799.17 compared to the previous period[21]. - The net cash flow from investing activities was -¥80,158,313.77, down from ¥101,958,136.28 in the previous period[21]. - Cash inflow from financing activities totaled ¥176,000,000.00, compared to ¥269,000,000.00 in the previous period[21]. - The net cash flow from financing activities was ¥38,049,967.89, an improvement from -¥72,014,597.20 in the previous period[21]. - The ending balance of cash and cash equivalents was ¥72,442,103.38, down from ¥90,115,539.62 in the previous period[21]. - The cash inflow from loans received was ¥147,000,000.00, compared to ¥240,000,000.00 in the previous period[21]. - Cash outflow for debt repayment was ¥99,450,000.00, down from ¥274,000,000.00 in the previous period[21]. - The cash outflow for dividend distribution and interest payments was ¥4,656,873.22, compared to ¥34,314,597.20 in the previous period[21]. - The impact of exchange rate changes on cash and cash equivalents was ¥7,531.94, compared to -¥16,768.56 in the previous period[21]. Assets and Liabilities - Total assets at the end of Q3 2023 amounted to CNY 1,341,192,183.09, reflecting a 3.65% increase from the end of the previous year[5]. - Current assets total CNY 367,244,999.44, a decrease from CNY 378,378,861.18 at the start of the year[14]. - Inventory has increased to CNY 78,313,347.14 from CNY 64,131,809.31 at the beginning of the year, reflecting a growth of approximately 22.1%[14]. - The company's cash and cash equivalents decreased to CNY 72,442,103.38 from CNY 95,068,123.47, a decline of about 23.8%[13]. - Non-current assets total CNY 973,947,183.65, up from CNY 915,566,549.11 at the beginning of the year[14]. - The total liabilities amount to CNY 344,737,918.45, an increase from CNY 317,045,536.08 at the start of the year[14]. - The total liabilities increased to CNY 367,557,459.00 from CNY 343,379,013.86, reflecting a rise of 7.0%[18]. - Total equity attributable to shareholders rose to CNY 973,634,724.09, up from CNY 950,566,396.43, an increase of 2.5%[18]. Expenses - Research and development expenses surged to CNY 31,900,346.61, marking a 121.45% increase due to the initiation of multiple new projects[8]. - Research and development expenses increased significantly to CNY 31,900,346.61, up from CNY 14,405,381.84, indicating a focus on innovation[17]. - The company experienced a 34.49% increase in non-operating expenses, primarily due to donations and fixed asset write-offs[9]. - Sales expenses decreased to CNY 180,025,425.29 from CNY 186,390,916.67, showing improved cost management[17]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,428[10]. - The largest shareholder, Cao Yuping, holds 42.08% of the shares, amounting to 50,491,306 shares, with 3,200,000 shares pledged[10]. Audit and Reporting - The company did not undergo an audit for the third quarter report[22].

证券代码：300584 证券简称：海辰药业 公告编号：2023-030 南京海辰药业股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况说明 南京海辰药业股份有限公司（以下简称"公司"或"本公司"）股票交易价 格连续两个交易日（2023 年 10 月 12 日和 2023 年 10 月 13 日）内收盘价格涨幅 偏离值累计超过 30%。根据深圳证券交易所的有关规定，属于股票交易异常波动 的情况。 二、公司关注并核实的情况说明 针对公司股票交易异常波动情况，公司董事会向控股股东、相关人员进行了 核实，现就有关核实情况说明如下： 1、公司前期披露的信息，不存在需要更正、补充之处； 2、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生 重大影响的未公开重大信息； 3、公司近期经营情况正常，内外部经营环境未发生重大变化； 4、经核查，公司、控股股东和实际控制人不存在关于本公司的应披露而未 披露的重大事项，也不存在处于筹划阶段的重大事项； 5、经核查，控股股东和实际控制人在股票交易异常波动期间不存在 ...

| | 共建研究中心，进而打造新的技术平台？ | | --- | --- | | | 答：尊敬的投资者您好，感谢您对公司的关注和建议！公司正在积极考虑 | | | 与高校合作，合作方式包括但不限于新品种遴选及合作，共建技术平台等 | | | 方式。 | | | 4、贵司股价正值低点，有无回购计划？公司不考虑搞一轮股权激励，鼓 | | | 舞员工士气，重振公司业绩吗？ | | | 答：尊敬的投资者您好，感谢您对公司的关注和建议！公司目前暂无回购 | | | 计划，公司将视公司实际情况综合并积极考虑是否实施股权激励，未来如 | | | 有相关计划，将按照信息披露相关规定及时公告。 | | 其他情况说明 | 无 | | 附件清单 | 无 | | （如有） | | | 日期 | 2023.9.26 | 2 2023 年半年度网上业绩说明会 暨投资者关系活动记录表 编号：2023-002 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 √业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 （请文字说明其他活动内容） | | 参 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 南京海辰药业股份有限公司（以下简称"公司"）于 2023 年 8 月 23 日在 巨潮资讯网（www.cnino.com.cn）披露了 2023 年半年度报告及摘要。为方便广 大投资者进一步了解公司 2023 年半年度报告及经营情况，公司定于 2023 年 9 月 26 日（星期二）下午 15：00-16：00 举行 2023 年半年度业绩说明会。本次 说明会将采用网络远程方式举行，投资者可登录深交所互动易云访谈平台 （http://irm.cninfo.com.cn/views/interview）参与本次半年度业绩说明 会。 证券代码：300584 证券简称：海辰药业 公告编号：2023-029 南京海辰药业股份有限公司 关于举行 2023 年半年度业绩网上说明会的公告 出席本次业绩说明会的人员有：公司董事长、总经理曹于平先生；董事会 秘书、副总经理王立先生；财务总监陈建仁先生。 为提高交流效率，公司现提前向投资者征集相关问题，广泛听取投资者的意 见和建议。投资者可于 2023 年 9 月 25 日（星期一） ...

证券代码：300584 证券简称：海辰药业 公告编号：2023-028 南京海辰药业股份有限公司 基于对公司未来发展的信心及对公司价值的充分认可,促进公司持续、稳定、 健康发展，以实际行动维护资本市场稳定和公司股东利益，公司控股股东、实际 控制人及持有公司股份的其他董监高自愿承诺:自签订承诺书起六个月内(即 2023 年 9 月 14 日至 2024 年 3 月 13 日)不减持本人直接持有的公司股份，包括 承诺期间该部分股份因资本公积转增、派送股票红利、配股、增发等事项产生的 新增股份。 二、上市公司董事会责任 公司董事会将督促上述人员严格遵守承诺，并按照《公司法》、《证券法》 以及中国证监会、深圳证券交易所相关法律法规、规范性文件的规定，及时履行 相关信息披露义务。 三、备查文件 1、上述承诺主体出具的《关于未来六个月内不减持公司股份的承诺函》。 特此公告！ 关于公司控股股东、实际控制人及董监高 承诺不减持公司股份的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 南京海辰药业股份有限公司（以下简称"公司"）近日收到了公司控股股东、 实际控制人曹于平先 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥261,547,849.93, a decrease of 2.25% compared to ¥267,578,608.53 in the same period last year[24]. - Net profit attributable to shareholders increased by 9.89% to ¥19,474,926.52 from ¥17,721,523.59 year-on-year[24]. - Basic and diluted earnings per share rose by 9.88% to ¥0.1623 compared to ¥0.1477 in the same period last year[24]. - The net profit attributable to shareholders was 19.47 million yuan, an increase of 9.89% year-on-year, while the net profit excluding non-recurring items rose by 11.05% to 18.88 million yuan[40]. - The company reported a total comprehensive income of CNY 19,474,926.00 for the first half of 2023, compared to CNY 17,721,523.50 in the same period of 2022, representing an increase of approximately 9.9%[172]. - The company's total comprehensive income for the first half of 2023 was CNY 28,321,181.14, compared to CNY 23,847,193.40 in the same period of 2022, reflecting an increase of 18.3%[165]. Cash Flow and Investments - The net cash flow from operating activities improved significantly to ¥6,280,246.52, a turnaround of 118.13% from a negative cash flow of ¥34,649,138.87 in the previous year[24]. - The cash inflow from financing activities in the first half of 2023 was CNY 106,000,000.00, while cash outflow for debt repayment was CNY 79,000,000.00, resulting in a net inflow of CNY 19,956,587.86[170]. - The net cash flow from investment activities for the first half of 2023 was CNY 51,904,399.82, compared to CNY 119,114,493.60 in the same period of 2022, indicating a decrease of approximately 56.4%[170]. - Investment activities resulted in a net cash outflow of CNY -27,868,369.08, a decline from a net inflow of CNY 115,658,146.82 in the first half of 2022[167]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,321,048,611.92, reflecting a 2.09% increase from ¥1,293,945,410.29 at the end of the previous year[24]. - The total liabilities increased to CNY 350,889,636.48 from CNY 343,379,013.86, reflecting a rise of approximately 2.2%[154]. - The company's equity attributable to shareholders reached CNY 970,158,975.44, up from CNY 950,566,396.43, indicating an increase of about 2.1%[154]. - Current assets totaled CNY 394,041,482.02, up from CNY 378,378,861.18, indicating an increase of about 4.4%[152]. - The company's short-term borrowings rose to CNY 157,120,774.96 from CNY 120,095,819.46, marking an increase of about 30.8%[154]. Research and Development - The management highlights ongoing efforts in research and development to enhance product offerings and market competitiveness[17]. - Research and development expenses increased by 53.65% to ¥28,008,748.18, attributed to the initiation of multiple new R&D projects[61]. - The company is actively investing in R&D to enhance product quality and competitiveness, with one product approved during the reporting period[46]. - The company has developed a new synthesis process for Tigecycline, becoming one of the few domestic companies capable of stable production of both the raw material and formulation[46]. - The company plans to continue focusing on R&D and market expansion strategies to drive future growth[162]. Market and Product Development - The company has 66 approved formulations and 13 active pharmaceutical ingredients, focusing on therapeutic areas such as cardiovascular, diuretics, anti-infection, digestive system, immune regulation, diabetes, and orthopedics[32]. - The company’s main products include injectable Labetalol, Torasemide, Rivaroxaban, Tigecycline, and Cefoperazone Sodium, with a strong emphasis on clinical value and innovation[32]. - The sales of key products, including injection-grade Labetalol, Rivaroxaban tablets, and Tigecycline, showed significant growth compared to the same period last year, positively impacting the company's performance[41]. - The company is in the registration process for several drugs, including injection-grade Azithromycin and Torasemide, which are expected to enrich its product pipeline[47]. Environmental Compliance - The company emphasizes the importance of environmental compliance and plans to increase investment in environmental protection measures[81]. - The company has obtained relevant environmental protection administrative permits, including a pollution discharge permit valid until August 31, 2027[93]. - The company has established a wastewater treatment facility to manage and reduce pollutant discharge effectively[95]. - The company has implemented measures to ensure that all emissions are compliant with GB/T319-62-2015 standards[95]. - The company has conducted multiple emergency response drills for environmental incidents and revised its emergency measures accordingly[100]. Shareholder and Governance - The company emphasizes the protection of shareholder interests and has established a governance structure to ensure compliance with laws and regulations[103]. - The company held its annual general meeting on May 15, 2023, with an investor participation rate of 52.68%[86]. - The company plans not to distribute cash dividends or issue bonus shares for the first half of the year[88]. - The company has not engaged in any derivative investments or entrusted loans during the reporting period[74][75]. Risks and Challenges - The company faces risks including changes in industry policies, new drug development risks, and market share decline of its main product, Torasemide[5]. - The company acknowledges risks from management expansion and aims to improve its management model to adapt to growth[81]. - The company plans to enhance its R&D capabilities and expedite the registration process for Torasemide tablets to mitigate market share decline[79].

南京海辰药业股份有限公司 2023年1-6月非经营性资金占用及其他关联资金往来情况汇总表 非经营性资金占用 资金占用方名称 占用方与上市公司的 关联关系 上市公司核算的 会计科目 2023年期初往来 资金余额 2023年1-6月往来累 计发生金额（不含 利息） 2023年1-6月往 来资金的利息 （如有） 2023年1-6月偿 还累计发生金额 2023年6月末往 来资金余额 占用形成原因 占用性质 小计 小 计 0.00 其他关联方及其附属企业 小 计 总计 0.00 0.00 0.00 0.00 其它关联资金往来 资金往来方名称 往来方与上市公司的 关联关系 上市公司核算的 会计科目 2023年期初往来 资金余额 2023年1-6月往来累 计发生金额（不含 利息） 2023年1-6月往 来资金的利息 （如有） 2023年1-6月偿 还累计发生金额 2023年6月末往 来资金余额 往来形成原因 往来性质 镇江德瑞药物有限公司 子公司 其他应收款 6,151.99 11,672.86 10,740.98 7,083.87 往来款 非经营性往来 安徽海辰药业有限公司 子公司 其他应收款 3,500.00 3,63 ...

证券代码：300584 证券简称：海辰药业 公告编号：2023-027 南京海辰药业股份有限公司 关于 2023 年度对下属子公司提供担保额度预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保额度预计情况 1、南京海辰药业股份有限公司（以下简称"公司""海辰药业"）于 2023 年 8 月 22 日召开了第四届董事会第九次会议，审议通过了《关于 2023 年度对下 属子公司提供担保额度预计的议案》，为满足公司及子公司经营和业务发展需求， 保证生产经营活动顺利开展，预计 2023 年度为全资子公司安庆汇辰药业有限公 司（以下简称"安庆汇辰"）提供额度不超过 5,000 万元人民币（或等值外币） 的担保，以上担保额度事项的期限为一年，在最高限额内可循环滚动使用，担保 范围包括但不限于申请综合授信、贷款、承兑汇票、信用证等融资业务，实际担 保金额、种类、期限等以签署的协议为准，同时授权公司董事长或董事长指定的 授权代表人代表公司办理相关手续、签署相关法律文件。 2、根据《深圳证券交易所创业板股票上市规则》、《公司章程》等相关规 定，本次担保预计额度 ...

独立董事关于第四届董事会第九次会议 相关事项的独立意见 根据《上市公司独立董事规则》《上市公司治理准则》、深圳证券交易所《创 业板股票上市规则》、深圳证券交易所《上市公司自律监管指引第 2 号——创业 板上市公司规范运作》《关于规范上市公司对外担保行为的通知》（证监发 [2005]120 号）、以及《公司章程》《独立董事工作制度》等相关法律法规、规 章制度的有关规定，我们作为南京海辰药业股份有限公司（以下简称"公司"） 的独立董事，基于独立判断的立场，本着实事求是的原则，对公司下列事项进行 了认真核查和了解，并对公司相关事项发表了如下独立意见： 南京海辰药业股份有限公司 三、对《2023 年度对下属子公司提供担保额度预计的议案》的独立意见 公司本次担保额度预计是为满足下属子公司日常生产经营的资金需求，有利 于子公司业务开展，符合公司整体发展战略，不会对公司的正常运作造成不利影 响。本次被担保对象为公司合并报表范围内的子公司，资信状况良好，为其提 供 担保的财务风险处于公司可控范围内。本次担保额度预计事项的审议和表决程 序符合相关法律法规及《公司章程》的规定，不存在损害公司及股东特别是中小 股东利益的情形。我们 ...